Warning Letter — Ong Tien USA LLC
The FDA issued a Warning Letter to Ong Tien USA LLC following a review by the Center for Drug Evaluation and Research (CDER).
This affects Ong Tien USA LLC and potentially other distributors or manufacturers of similar products regulated under CDER jurisdiction. Operative impact is primarily on regulatory and quality compliance departments.
The issuance of a Warning Letter by CDER indicates that the FDA has identified significant violations of the Federal Food, Drug, and Cosmetic Act. While the source excerpt does not detail specific product names or violations, such letters typically involve issues such as marketing unapproved new drugs or misbranding, which can lead to seizure, injunction, or civil money penalties if not remediated. Regulatory teams should interpret this as a signal of continued FDA oversight on drug distribution compliance.
Review all current product listings and marketing materials to ensure they align with approved drug applications. Organizations should conduct a gap analysis of their product portfolio to identify any items being marketed for drug-like indications without necessary FDA licensure or cleared applications.
FDA Warning Letter issued to: Ong Tien USA LLC. 10/26/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ong-tien-usa-llc-737352-10262026
Open in openFDA / FDA.gov